June 20, 2010
3‐V Biosciences, Inc. today announced the appointment of James F. Young, Ph.D. to its Board of Directors.

“We are very pleased to welcome Jim Young to the 3‐V Board,” said David M. Mott, 3‐V’s Executive Chairman. “Jim’s expertise as a virologist, immunologist, drug developer and company builder make him extraordinarily well suited to assist 3‐V in its mission to build the leading host cell factor anti-°©‐infective company. Jim has a great nose for science and the experience and wisdom in drug development gained from having been head of R&D at MedImmune for 19 years, from its founding until 2008 following its sale to AstraZeneca for $15.6 billion. Uniquely suited to 3‐V’s initial focus, Jim has particular expertise in discovering, developing and commercializing products targeting viruses including influenza, respiratory syncytial virus, human papillomavirus, and cytomegalovirus.”

Most recently, Dr. Young graduated first in his class with a Certificate de Cuisine from Le Cordon Bleu Academie d’Art Culinaire de Paris in Paris, France. He currently serves...read more

June 06, 2010
3-V Biosciences, Inc. announced today the appointment of Edward M. Connor, Jr., MD, as Chief Medical Officer

“Ed Connor is among the most experienced respiratory infectious disease drug developers in the world, having led the development of RespiGam and Synagis® for respiratory syncytial virus and FluMist® for influenza,” said David M. Mott, 3-V’s Executive Chairman.  “He has further extensive experience in infectious disease, immunology and oncology from his role as Executive Vice President and Chief Medical Officer at MedImmune, where he spent 14 years until 2008 following MedImmune’s sale to AstraZeneca.”

At 3-V, Dr. Connor will be responsible for directing all medical activities and will work with the senior management group to select targets, develop target product profiles...read more

May 13, 2010
3-V Biosciences Expands Leadership Team, Opens New Facility and Integrates Operations

Menlo Park, California, May 13, 2010. 3-V Biosciences, Inc. announced today the appointment of Stephen R. Brady to the post of Vice President, Corporate Development, Strategy & Operations, the consolidation of all preclinical research under Robert S. McDowell, Ph.D. as Vice President, Research, and the integration of the company into new office and lab space in Menlo Park, California.

“We are very pleased to welcome Steve Brady to the 3-V team, and to expand Bob McDowell’s responsibilities within the organization, “ said David M. Mott, the company’s Executive Chairman. “Steve’s broad business experience across a spectrum of innovative biopharmaceutical companies and Bob’s extensive background in, and leadership of, small-molecule drug discovery and development, will provide two critical elements as we continue to build and scale 3-V. ”...read more



July 10, 2009
3-V Biosciences, Inc. Secures $30 Million in Series B Funding, Welcomes New Members to Board of Directors

Palo Alto, Calif. – July 10, 2009 – 3-V Biosciences, a privately held biotechnology company dedicated to discovering and developing novel therapeutics for human infectious diseases, today announced it has secured $30 million in Series B funding. The financing was led by new investor New Enterprise Associates (NEA) and includes the participation of the existing investors Kleiner Perkins Caufield & Byers (KPCB) and The Column Group (TCG). The capital will be used for both exploratory research and early clinical development of the company’s lead programs targeting the treatment of respiratory viral infections...read more



March 26, 2009
3-V Biosciences Presents at NIAID Influenza Antiviral
Development Workshop

The National Institute of Allergy and Infectious Diseases (NIAID) conducted a workshop on the current state of Influenza drug development, including new strategies targeting the host response to infection. 3-V Biosciences’ Founder Dr. Ari Helenius and CEO Dr. John Curnutte gave invited presentations at the workshop (summary linked below).

Dr. Helenius (see page 3) discussed 3-V Biosciences’ host-directed systems biology approach to discover novel targets for antiviral drug development.  Dr. Curnutte (see page 9) presented preclinical data for compounds in 3-V’s lead antiviral program that exhibit potent activity against Influenza, including H5N1 Avian Flu.

http://www3.niaid.nih.gov/topics/flu/PDF/fluantiviral09.pdf